ASCO Annual Meeting | Conference

Dr. Taplin on Neoadjuvant Abiraterone and Leuprolide

June 8th 2012

Dr. Mary-Ellen Taplin, from Dana-Farber Cancer Institute, on Neoadjuvant Abiraterone Acetate and Leuprolide Acetate

Dr. Brahmer on the PD-1 Immunotherapy BMS-936558

June 7th 2012

Dr. Julie Brahmer, from the Sidney Kimmel Comprehensive Cancer Center, on the PD-1 Immunotherapy BMS-93655 Clinical Trial

Dr. Larsen Discusses Outcomes for AYA ALL Patients

June 7th 2012

Dr. Eric Larsen, from the Maine Children's Cancer Program, Discusses Outcomes for AYA Patients With Acute Lymphoblastic Leukemia

ASCO President Recaps Top Stories From Meeting

June 6th 2012

Dr. Michael P. Link, ASCO President, from Stanford University School of Medicine, on the top stories from the 2012 ASCO Annual Meeting.

2012 ASCO Annual Meeting Slideshow

June 6th 2012

Photos taken at the 2012 ASCO Annual Meeting held at the McCormick Place in Chicago, Illinois, from June 1-5, 2012.

Dr. Wood on Family Histories and Genetic Counseling

June 5th 2012

Dr. Marie Wood, from the University of Vermont, on Family Histories and Genetic Counseling for Breast and Colorectal Cancers.

Two Newer Breast Cancer Therapies Not Superior to Standard Paclitaxel, Study Suggests

June 5th 2012

The newer and more expensive breast cancer treatments nab-paclitaxel and ixabepilone, failed to demonstrate superior efficacy versus standard care with weekly paclitaxel.

Study Finds Cymbalta Reduces Peripheral Neuropathy Pain

June 5th 2012

The antidepressant duloxetine relieved pain associated with chemotherapy-induced peripheral neuropathy for 59% of patients.

Pilot Study Evaluates a Proposed Quality Measure for Family History Collection and Genetic Testing Referral

June 5th 2012

Only half of those with breast cancer and one-quarter of those with colon cancer were referred for genetic counseling or testing by their physicians.

FDA and Industry Collaborating to Prevent Cancer Drug Shortages

June 5th 2012

Drug manufacturers are working with the FDA to report anticipated shortages earlier and ensure alternative sources of needed drugs are available.

Dr. Rugo on Paclitaxel Superiority in Advanced Breast Cancer

June 5th 2012

Dr. Hope Rugo, from the UCSK Comprehensive Cancer Center, on the First-line Superiority of Paclitaxel for Advanced Breast Cancer.

Two New BRAF-Targeted Therapies Reduce Disease Progression in Advanced Melanoma Patients

June 4th 2012

Trametinib and dabrafenib delayed disease progression and showed a trend toward improved survival in patients with advanced melanoma.

Dr. Robert on the Trametinib METRIC Trial Results

June 4th 2012

Dr. Caroline Robert, from the Institute Gustave Roussy in Paris, France, Discusses the MEK Inhibitor, Trametinib, METRIC Trial Results.

Dr. Demetri Discusses Regorafenib for GIST Patients

June 4th 2012

Dr. George Demetri, from Dana-Farber Cancer Institute, Discusses Regorafenib for Patients with GIST Trial Results.

Regorafenib Offers New Hope for Patients With Treatment-Resistant GIST

June 4th 2012

The oral multikinase inhibitor regorafenib reduced the risk of disease progression by 73% in patients with gastrointestinal stromal tumors who had exhausted all other treatment options.

Afatinib Prolongs PFS in Lung Cancer Trial

June 4th 2012

Afatinib markedly prolonged PFS compared with standard chemotherapy in patients with advanced lung adenocarcinomas that tested positive for EGFR mutations, particularly one of two common mutation types.

Bevacizumab Plus Second-Line Chemotherapy Extends Survival in Advanced Colorectal Cancer Patients

June 3rd 2012

Bevacizumab plus chemotherapy as a second-line treatment for metastatic colorectal cancer improved survival among patients whose disease had progressed after first-line combination therapy with bevacizumab.

Dr. Blackwell Discusses the T-DM1 EMILIA Trial

June 3rd 2012

Dr. Kimberly Blackwell, from the Duke Cancer Institute, Discusses the T-DM1 EMILIA Trial

Dr. Rummel on Treanda Plus Rituxan in Indolent Lymphoma

June 3rd 2012

Dr. Mathias Rummel, from University Hospital Giessen in Germany, on Bendamustine Plus Rituximab in Indolent and Mantle Cell Lymphomas

Antibody Drug Conjugate T-DM1 Improves PFS in HER2-Positive Breast Cancer

June 3rd 2012

T-DM1 extended progression-free survival by 3.2 months in women with HER2-positive locally advanced or metastatic breast cancer.